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PMH36
DOSING OF BENZODIAZEPINE HYPNOTICS IN 
ELDERLY PATIENTS
Young JK, Schultz D, Foster D, Heller S
Solucient, Ann Arbor, MI, USA
OBJECTIVES: Use of benzodiazepines in elderly patients
has been associated with adverse outcomes including mo-
tor vehicle accidents and hip fractures from falls. Evi-
dence exists showing greater risk of adverse outcomes
with higher doses of these drugs regardless of drug half-
life. Initial administration of lower doses to elderly and
debilitated patients is generally recommended for benzo-
diazepine hypnotics. We analyzed whether these recom-
mendations are generally followed when prescribing
these drugs to inpatients. METHODS: Demographic and
hospital information for all patients receiving fluraze-
pam, triazolam, or temazepam between January 1998
and June 2000 was extracted from Solucient’s Projected
Inpatient International Classification of Clinical Services
(pICCS) database. This database contains demographic,
hospital, clinical, and detailed service level information
for inpatients from over 150 short-term, non-federal, US
hospitals. The percent of elderly patients (over age 65) re-
ceiving the recommended dose was determined. The rela-
tionship of patient age, hospital teaching status, bed size,
and geographic region on the likelihood of following dos-
ing recommendations was analyzed. RESULTS: We ex-
tracted information for 14,929 inpatients receiving flu-
razepam, 8,147 inpatients receiving triazolam, and 125,625
patients receiving temazepam. Among elderly patients re-
ceiving one of these drugs, 72.1% of patients receiving
flurazepam, 49.8% of patients receiving temazepam, and
7.1% of patients receiving triazolam received the recom-
mended dose. For all three drugs, patient age was directly
correlated with the likelihood of receiving the recom-
mended dose. There was no consistent relationship be-
tween teaching status, hospital bed size, or geographic re-
gion and the likelihood of receiving the recommended
dose, although teaching hospitals were much more likely
than non-teaching hospitals to provide the recommended
dose for temazepam and triazolam (OR 5.3 CI 4.9–5.8
for temazepam; OR 2.7 CI 2.2–3.2 for triazolam). CON-
CLUSIONS: Many elderly inpatients are prescribed higher
than recommended doses of hypnotic benzodiazepines,
suggesting need for systemic interventions to avert ad-
verse outcomes.
PAIN & NEUROLOGIC DISORDERS
PPN1
AN INTERNET STUDY OF WTP FOR MIGRAINE 
PHARMACOTHERAPIES
Lenert LA, Minh C, Jackson C
University of California–San Diego, San Diego, CA, USA
BACKGROUND: There are a wide range of therapeutic
options for migraine headaches that have different costs
and benefits, and little is known about the cost-effective-
ness of specific therapies. OBJECTIVE: Assess patients’
preferences for outcomes of treatment of migraine head-
ache based on their marginal willingness to pay (WTP)
for treatment attributes. METHODS: In an Internet-
based study, we used computer software to measure im-
portance ratings of attributes of pharmacological mi-
graine therapies, then elicited their WTP for an ideal drug
(one that was 100% effective, worked quickly, and had
no adverse effects) and for “less than ideal” drugs with
relatively poor performance in one specific attribute of
performance. Patients: 429 self-identified migraineurs re-
cruited via an Internet web site. RESULTS: A high pro-
portion of patients in the study had symptoms consistent
with migraine etiology of headache (91% in enrollees,
99% of patients providing WTP ratings). Expert review
confirmed a large proportion of symptom profiles as be-
ing consistent with migraine (90% of the first 109 enroll-
ees). Median WTP for an ideal migraine therapy was
4.1% of estimated monthly income or $130 (US), and
was associated with severity of pain, frequency of head-
aches, and the types of medications used in the past.
WTP was reduced when pharmaceuticals offered less
benefit (median reductions of a $75 per month for 50%
chance of causing a rebound headache; $62 for rendering
user unable to work, $50 for a two-hour delay in effect;
and $15 for failure to relieve nausea). Reductions in WTP
were largely consistent with importance ratings for at-
tributes except for “speed of relief,” which was more
highly valued. CONCLUSIONS: Elicitation of patients’
WTP for specific attributes of a therapy appears to be a
feasible method to quantify patients’ preferences for out-
comes. Further work is needed to compare this approach
to traditional methods for measurement of WTP.
PPN2
USE OF GALANTAMINE IN THE NETHERLANDS 
FOR THE TREATMENT OF MILD TO MODERATE 
ALZHEIMER’S DISEASE
Caro J1, Salas M1, Getsios D1, Mehnert A2, for the AHEAD 
Study Group
1Caro Research Institute, Concord, MA, USA; 2Janssen 
Research Foundation, Beerse, Belgium
OBJECTIVES: To estimate the costs and long-term
health effects of using galantamine in Dutch patients with
mild to moderate Alzheimer’s disease (AD). METHODS:
A pharmacoeconomic model was developed. It consists
of two components: an initial module based on two gal-
antamine clinical trials and a subsequent module that
uses trial results and equations derived from recently
published data to forecast the time until patients require
full time care (FTC) or die. The analyses compare treat-
ment with galantamine 24 mg to no pharmacologic treat-
ment. Cost estimates were based on resource use profiles
of patients with AD in the Netherlands and are reported
in 1998 guilders (NLG) determined from the perspective
of a comprehensive care payer. Future costs are dis-
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counted at a 5% annual rate. Extensive sensitivity analy-
ses were conducted. RESULTS: Over the decade of anal-
ysis, a net saving of NLG 3,050 was estimated. The cost
of galantamine makes up 5.0% of the total. The model
predicts that patients treated with galantamine are ex-
pected to spend 10.0% less time receiving home-based
FTC and 9.9% less time in a nursing home compared to
untreated patients. For every hundred patients starting
treatment on galantamine 17.8 person-years of FTC are
avoided (14.3 discounted). Secondary analyses of the ef-
fect of galantamine on behavioral symptoms estimated an
increment in total savings of NLG 4,903. Sensitivity anal-
yses run on key model parameters showed results to be
robust. CONCLUSION: On average, treatment with gal-
antamine not only provides a considerable health benefit
but is also expected to yield savings in the costs associ-
ated with mild to moderate AD in the Netherlands.
PPN3
THE IMPACT OF DEMENTIA ON CAREGIVER 
QUALITY OF LIFE
Gold KF1, Botteman MF1, Kemp R2, Kittner B2, Pashos CL1
1Abt Associates Clinical Trials, Bethesda, MD, USA; 2Aventis, 
Bridgewater, NJ, USA
BACKGROUND: The prevalence of Alzheimer’s disease
(AD) and vascular dementia (VD) is expected to rise sub-
stantially in the coming decades. As well, the impact of
these conditions on caregiver burden and quality of life
(QOL) is also expected to increase. OBJECTIVES: To (1)
determine how the characteristics of patients and their
caregivers affects caregiver’s QOL, and (2) identify sub-
sets of caregivers disproportionately affected by their pa-
tient’s disease. METHODS: Data were collected cross-
sectionally at baseline on 912 pairs of AD/VD patients
and their primary caregivers as part of a multinational
prospective longitudinal clinical trial. Patient and care-
giver demographics, patient CDR and DAD scores were
collected, as were caregiver EuroQol (EQ-5D) scores and
time spent on caregiving activities. Univariate and multi-
variate analyses were conducted to determine patient and
caregiver characteristics that were particularly associated
with low caregiver QOL. RESULTS: Patient severity as
measured by CDR score was moderately related to care-
giver EuroQol score (p  .05). Specifically, caregiver Eu-
roQol scores were .84, .78, .76, and .74 for questionable,
mild, moderate, and severe dementia (on the CDR), re-
spectively. In a main-effects only regression model, a
4-point and a 7-point reduction in caregiver’s EuroQol
score was associated with the caregiver being a women
and being a spouse/partner of the patient, respectively.
When an interaction term between these two variables
was introduced into the regression, the main effects of
caregiver gender and being a spouse/partner of the pa-
tient became insignificant. However, the interaction
term, being a woman spouse caring for a patient, was as-
sociated with a significant 12-point reduction in EuroQol
score. CONCLUSIONS: Worse caregiver QOL is associ-
ated with more severe patient disease stage and with be-
ing a woman caring for a demented spouse. Interventions
should thus be planned with special consideration given
this potentially more vulnerable set of caregivers.
PPN4
UTILITY ASSESSMENTS OF OPIOID 
TREATMENT IN THE US, CANADA AND 
AUSTRALIA FOR PATIENTS WITH CHRONIC 
NON-MALIGNANT PAIN
Schmier J1, Palmer C1, Ingham M2, Mathur S1, Dodd S3, 
Gourlay G4
1MEDTAP International Inc, Bethesda, MD, USA; 2Janssen-
Ortho Inc, Toronto, ON, Canada; 3Janssen Pharmaceutica, 
Titusville, NJ, USA; 4Flinders Medical Centre, Bedford Park, 
Australia
BACKGROUND: Optimal treatment for chronic non-
malignant pain (CNMP) is largely a function of patient
preferences in balancing pain control with treatment tol-
erability. OBJECTIVE: To estimate utilities for health
states associated with CNMP and its treatment with opi-
oids. METHODS: 96 CNMP patients (31 Canadian, 33
US, 32 Australian) completed the SF-36TM and assessed
health state descriptions and their own current health us-
ing the visual analog scale and computer-assisted adap-
tive conjoint analysis (ACA). The health state descrip-
tions included combinations of: presence/absence of 7
side effects (3 severity levels for each); pain control (5 se-
verity levels); and 2 opioid administration routes. RE-
SULTS: On average, subjects were 47 (13) years, white
(95%), female (63%), not living alone (74%), and unem-
ployed (74%). Approximately 75% of subjects in each
country were currently experiencing mild to moderate
pain; most had arthritic or low back pain. All SF-36TM
subscale scores by country were significantly lower than
US age- and gender-equivalent norms (p  0.05). Mean
utilities did not vary substantially between oral vs. trans-
dermal opioid administration. Overall, mean (SE) utili-
ties ranged from a maximum of 0.87  0.02 (no pain or
side effects) to a minimum of 0.18  0.02 (uncontrolled
pain with severe respiratory depression or severe vomit-
ing). Mean utilities for controlled pain with moderate
side effects ranged from 0.62  0.02 (mood changes,
vomiting, or respiratory depression) to 0.74  0.02
(sweating). Uncontrolled pain without side effects (0.64 
0.02) was preferred to well-controlled pain with severe
side effects (range: 0.41  0.03 [mood changes, vomit-
ing, or respiratory depression] to 0.54  0.03 [sweat-
ing]). CONCLUSIONS: Results indicate a patient prefer-
ence for opioid therapy that causes fewer side effects.
Although pain may be extremely debilitating, tolerating
pain to avoid opioid side effects may be preferable to
controlling pain and experiencing certain opioid side ef-
fects. Opioid side effects combined with poorly-con-
trolled pain may result in very low health utility.
